Exatecan is a drug which is a structural analog of camptothecin with antineoplastic activity.[1]
Names | |
---|---|
Preferred IUPAC name
(1S,9S)-1-Amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-10,13-dione | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C24H22FN3O4 | |
Molar mass | 435.455 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
A derivative is used in Trastuzumab deruxtecan.
Synthesis
editReferences
edit- ^ Abou-Alfa, GK; Letourneau, R; Harker, G; Modiano, M; Hurwitz, H; Tchekmedyian, NS; Feit, K; Ackerman, J; De Jager, RL; Eckhardt, SG; O'Reilly, EM (20 September 2006). "Randomized Phase III Study of Exatecan and Gemcitabine Compared with Gemcitabine Alone in Untreated Advanced Pancreatic Cancer". Journal of Clinical Oncology. 24 (27): 4441–7. doi:10.1200/JCO.2006.07.0201. PMID 16983112.
- ^ H. Terasawa, A. Ejima, S. Ohsuki, K. Uoto, U.S. Patent 5,834,476 (1998).